Janse van Rensburg H, Spiliopoulou P, Siu L
Oncologist. 2022; 27(5):352-362.
PMID: 35285488
PMC: 9074993.
DOI: 10.1093/oncolo/oyac047.
Lee H, Yun S, Kim J, Ryu C
Eur Radiol. 2019; 30(1):588-599.
PMID: 31418086
DOI: 10.1007/s00330-019-06377-4.
Zare N, Eskandari N, Mehrzad V, Javanmard S
J Res Med Sci. 2019; 24:10.
PMID: 30988678
PMC: 6421886.
DOI: 10.4103/jrms.JRMS_507_18.
Mizia-Stec K, Elzbieciak M, Wybraniec M, Rozewicz M, Bodys A, Braksator W
Med Oncol. 2017; 35(1):14.
PMID: 29274027
PMC: 5741777.
DOI: 10.1007/s12032-017-1075-2.
Gonzalez-Barca E, Canales M, Salar A, Ferreiro-Martinez J, Ferrer-Bordes S, Garcia-Marco J
Ann Hematol. 2016; 95(6):893-9.
PMID: 27025508
PMC: 4853453.
DOI: 10.1007/s00277-016-2648-4.
Switching to BCL-6 Negativity in Relapsed Diffuse Large B Cell Lymphoma Correlated with More Aggressive Disease Course.
Todorovic M, Balint B, Andjelic B, Radisavljevic Z, Mihaljevic B
Indian J Hematol Blood Transfus. 2014; 30(4):269-74.
PMID: 25435726
PMC: 4243415.
DOI: 10.1007/s12288-014-0346-8.
Immunohistochemical (IHC) Analysis of Non-Hodgkin's Lymphoma (NHL) Spectrum According to WHO/REAL Classification: A Single Centre Experience from Punjab, India.
Sharma M, Mannan R, Madhukar M, Navani S, Manjari M, Bhasin T
J Clin Diagn Res. 2014; 8(1):46-9.
PMID: 24596721
PMC: 3939585.
DOI: 10.7860/JCDR/2014/8173.3988.
Safety and efficacy of bevacizumab combined with R-CHOP regimen in seven Chinese patients with untreated diffuse large B-cell lymphoma.
Fu Z, Zhu J, Zheng W, Liu W, Ying Z, Xie Y
Cancer Cell Int. 2014; 14(1):5.
PMID: 24438119
PMC: 3897913.
DOI: 10.1186/1475-2867-14-5.
How we treat Richter syndrome.
Parikh S, Kay N, Shanafelt T
Blood. 2014; 123(11):1647-57.
PMID: 24421328
PMC: 3954047.
DOI: 10.1182/blood-2013-11-516229.
Improvement of hospital care for patients with non-Hodgkin's lymphoma: protocol for a cluster randomized controlled trial (PEARL study).
Stienen J, Hermens R, Wennekes L, van de Schans S, Dekker H, Blijlevens N
Implement Sci. 2013; 8:77.
PMID: 23837833
PMC: 3711783.
DOI: 10.1186/1748-5908-8-77.
Limited role for surveillance PET-CT scanning in patients with diffuse large B-cell lymphoma in complete metabolic remission following primary therapy.
Cheah C, Hofman M, Dickinson M, Wirth A, Westerman D, Harrison S
Br J Cancer. 2013; 109(2):312-7.
PMID: 23807169
PMC: 3721385.
DOI: 10.1038/bjc.2013.338.
Improving survival and preventing recurrence of diffuse large B-cell lymphoma in younger patients: current strategies and future directions.
Karlin L, Coiffier B
Onco Targets Ther. 2013; 6:289-96.
PMID: 23579927
PMC: 3621721.
DOI: 10.2147/OTT.S42574.
Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties.
Klein C, Lammens A, Schafer W, Georges G, Schwaiger M, Mossner E
MAbs. 2012; 5(1):22-33.
PMID: 23211638
PMC: 3564883.
DOI: 10.4161/mabs.22771.
The diffuse large B-cell lymphoma - where do we stand now in everyday clinical practice.
Gregoric B, Zadnik V, Novakovic B
Radiol Oncol. 2012; 46(2):153-9.
PMID: 23077452
PMC: 3472942.
DOI: 10.2478/v10019-012-0002-6.
Characteristics and Results of the Management of Diffuse Large B-Cell Lymphomas: The Experience of Côte d'Ivoire.
Tolo Diebkile A, Kouakou B, Ndhatz E, Nanho C, Meite N, Ayemou R
Adv Hematol. 2012; 2012:945138.
PMID: 22693514
PMC: 3368158.
DOI: 10.1155/2012/945138.
Proteasome inhibition and combination therapy for non-Hodgkin's lymphoma: from bench to bedside.
Mato A, Feldman T, Goy A
Oncologist. 2012; 17(5):694-707.
PMID: 22566373
PMC: 3360909.
DOI: 10.1634/theoncologist.2011-0341.
The role of autologous stem cell transplantation in the treatment of diffuse large B-cell lymphoma.
Gunnellini M, Emili R, Coaccioli S, Liberati A
Adv Hematol. 2012; 2012:195484.
PMID: 22312366
PMC: 3270517.
DOI: 10.1155/2012/195484.
